Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab

Uysal M., Bozcuk H., Göksu S. S., Tatlı A. M., Arslan D., Gunduz S., ...Daha Fazla

BIOMEDICINE & PHARMACOTHERAPY, cilt.68, sa.4, ss.409-412, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 68 Sayı: 4
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1016/j.biopha.2014.03.002
  • Dergi Adı: BIOMEDICINE & PHARMACOTHERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.409-412
  • Anahtar Kelimeler: Bevacizumab, Metastatic colorectal cancer, Prognostic and predictive factors, Proteinuria, PREOPERATIVE CARCINOEMBRYONIC ANTIGEN, FLUOROURACIL, LEUCOVORIN, HYPERTENSION, IRINOTECAN, OUTCOMES
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Background: The beneficial effects of bevacizumab, a widely used agent in metastatic colorectal cancer (mCRC), on clinical survival have been proven. This study investigated the correlation of the clinical benefits and prognosis with proteinuria and other parameters.